Charles Bankhead

Over the past 25 years, multiple lung cancer chemoprevention trials have missed the mark with agents that looked good on paper but lacked the molecular biology support to make a difference.

The results of a systematic review and meta-analysis suggest that the mortality risk for colon cancer patients begins to increase with any avoidable delay in adjuvant chemotherapy beyond 4 weeks.

Data from a large randomized trial showed that treatment with the targeted agent everolimus was associated with a 65% improvement in progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumors (PNETs).

The risk of colorectal cancer declined by 33% among postmenopausal women taking oral bisphosphonates for osteoporosis

In situ hybridization (ISH) yields the best results for assessing HER2 expression in gastric cancer, according to a multilaboratory analysis of testing methods.

An analysis of the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database showed that advanced gastric or esophageal cancer confers a poor prognosis

Patients with gastrointestinal stromal tumors (GIST) had stable plasma concentrations of imatinib during long-term treatment, reported Yoon-Koo Kang, MD, PhD, and colleagues at the Gastrointestinal Cancers Symposium.

The results of a large, multicenter trial showed that the addition of bevacizumab to adjuvant chemotherapy failed to improve disease-free survival (DFS) compared with chemotherapy alone.

At the 2011 symposium in San Francisco, California, Oncology & Biotech News spoke with the author of one of the featured presentations at the meeting

Few cancers have a bleaker outlook than pancreatic cancer.